Avacta Group Plc (AVCT.L)
Develops cancer drugs that deliver toxic chemotherapy directly to tumors
69.80+0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+48.5%
The outlook
AVCT.L is trading near the middle of its 52-week range with mixed momentum against its moving averages. Analyst coverage suggests an average price target around 17% above current levels, while the overall sentiment score sits neutral. Today's movement was minimal.
What’s behind the score
Price trendMixed vs its moving averages
52-week range56% of the way from its 52-week low to high
Price targetAvg target +17% vs current price
Analyst price target
~12-month · 3 analysts81.67average target+17.0% vs now
Now 69.80
Low 60.00High 101.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$327.0M
52-wk high
92.00
52-wk low
41.33
50-day avg
72.28
200-day avg
69.05
Trailing P/E
—